Terkko Navigator / Lancet Oncology

Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer

GDPR obstructs cancer research data sharing

AACR Annual Meeting 2021

Placenta can provide new insights on the genetics of cancer

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial

Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis

Are we already in the era of total neoadjuvant treatment for rectal cancer?

Next generation platinum salt in nasopharygeal carcinoma

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial

Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III–IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial

Increasing the value of radiotherapy in breast cancer

New technical guidance to boost global radiotherapy access

Symmetric bilateral liposarcoma in an interventional cardiologist

China's oncology drug market on the rise

Carcinogenicity of gentian violet, leucogentian violet, malachite green, leucomalachite green, and CI Direct Blue 218

Extent of French nuclear tests in Polynesia revealed

Real-time fluorescence imaging in intraoperative decision making for cancer surgery

ODA budget cuts will affect global cancer research

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

Should we or should we not? Secondary debulking in ovarian cancer

Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial

The Global Breast Cancer Initiative: a strategic collaboration to strengthen health care for non-communicable diseases

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised,

Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

Imaging: towards a global solution to overcome the cancer pandemic

The benefits of integrating medical imaging and nuclear medicine

Improving the view: the need for global action on universal access to cancer imaging

Public reporting of outcomes in radiation oncology: the National Prostate Cancer Audit

How can we achieve equitable global access to cancer imaging and care?

The importance of medical imaging and nuclear medicine in universal health coverage

Medical imaging and nuclear medicine: a Lancet Oncology Commission

A southeast Asia perspective on medical imaging and nuclear medicine

Pembrolizumab monotherapy in metastatic triple-negative breast cancer

Global access to medical imaging and nuclear medicine

Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan

Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial

Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomised, controlled, phase 3, superiority trial

Circulating tumour DNA in patients with melanoma receiving targeted therapy

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study